Point32 Health Cuts Jobs Amid Financial Strain
The second largest health insurer in Massachusetts, Point32 Health, announced a new round of layoffs, which saw an additional 254 employees let go this week. This decision comes as the company grapples with rising expenses related to medical and drug costs.
This latest wave of layoffs represents about 6.7% of its workforce of over 3,700 employees, as reported by The Boston Globe.
Previously, the company had already cut 110 positions back in March.
Point32 Health, which encompasses Harvard Pilgrim Health Care and Tufts Health Plan, stated that these cuts are part of efforts to manage administrative costs amid the ongoing rise in healthcare expenses.
Patrick Gilligan, the CEO, emphasized the importance of addressing costs within their control in a statement to the Globe. “Our members are at the heart of everything we do,” he said, underscoring the commitment to effectively manage administrative expenditures while facing industry challenges.
Point32 Health has not yet responded to requests for more information.
The layoffs come on the heels of an operating loss of $96 million, despite generating $4.9 billion in revenue through June. High spending on costly medications—including GLP-1 drugs, targeted immunomodulators like Skyrizi and Dupixent, oncology treatments, and drugs for cardiac amyloidosis—have significantly impacted their financial situation.
Rising medical costs, particularly for prescription drugs and hospital services, are creating challenges across the health insurance sector, as reported by the Boston Business Journal.
Glenn McFarlane, the interim CFO, commented earlier this month that while insurers are raising premiums, they often misjudge the rising drug costs they face. “This trend has taken all the major healthcare companies by surprise,” he noted.
Popular GLP-1 drugs, such as Ozempic and Wegovy, are cited as major contributors to the increased healthcare expenditure.
Point32 is projected to spend $70 million on GLP-1 drugs alone in 2024. Additionally, Blue Cross Blue Shield of Massachusetts allocated 20% of its pharmacy costs to these medications last year. While Blue Cross Blue Shield has yet to implement staff reductions, it has acknowledged the possibility of future layoffs, with CEO Sarah Iselin stating that such measures are under consideration.
